CABALETTA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.97 USD | -7.79% |
|
-22.00% | -38.46% |
| Mar. 22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
| Mar. 21 | Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 5.56M | Capitalization | 674M |
|---|---|---|---|---|---|
| Net income 2024 * | -92M | Net income 2025 * | -109M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 258M | Net cash position 2025 * | 181M | EV / Sales 2025 * | 88.8 x |
| P/E ratio 2024 * |
-7.38
x | P/E ratio 2025 * |
-6.62
x | Employees | 102 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cabaletta Bio, Inc.
More recommendations
More press releases
| 1 day | -7.79% | ||
| 1 week | -22.00% | ||
| Current month | -18.11% | ||
| 1 month | -22.30% | ||
| 3 months | -31.79% | ||
| 6 months | +3.83% | ||
| Current year | -38.46% |
1 week
13.79
17.56
1 month
13.7919.04
Current year
13.7926.35
1 year
7.6926.35
3 years
0.5926.35
5 years
0.5926.35
10 years
0.5926.35
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 17-03-31 | |
Anup Marda
DFI | Director of Finance/CFO | 46 | 18-12-31 |
| Compliance Officer | - | 19-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 19-02-18 | |
| Chief Executive Officer | 62 | 17-03-31 | |
Mark Simon
BRD | Director/Board Member | 62 | 18-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 13.97 | -7.79% | 1,145,261 |
| 24-04-17 | 15.15 | -7.00% | 1,133,859 |
| 24-04-16 | 16.29 | +0.68% | 649,758 |
| 24-04-15 | 16.18 | -4.99% | 1,019,200 |
| 24-04-12 | 17.03 | -4.91% | 1,005,158 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
13.97
USD
Average target price
34.5
USD
Spread / Average Target
+146.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.46% | 674M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.78% | 21.66B | |
| -18.35% | 20.77B | |
| -8.79% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- CABA Stock
